ALKEM LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,884 INR | -0.55% |
|
+2.90% | -6.13% |
| Apr. 16 | Alkem Laboratories Limited Receives A Demand Order Levying A Penalty of INR 35,099 State Tax Officer, Ghatak | CI |
| Mar. 28 | Alkem Laboratories Forms Subsidiary for Medical Devices Business | MT |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 209,340 | 278,090 | 331,171 | 432,909 | 406,055 | 587,112 | - | - |
| Enterprise Value (EV) 1 | 211,750 | 283,796 | 328,603 | 433,805 | 393,853 | 566,992 | 559,257 | 552,737 |
| P/E ratio | 27.5 x | 24.7 x | 20.9 x | 26.3 x | 41.3 x | 32.1 x | 27.2 x | 23.7 x |
| Yield | 0.91% | 1.07% | 1.01% | 0.94% | 0.74% | 0.88% | 0.99% | 1.11% |
| Capitalization / Revenue | 2.85 x | 3.33 x | 3.74 x | 4.07 x | 3.5 x | 4.55 x | 4.13 x | 3.75 x |
| EV / Revenue | 2.88 x | 3.4 x | 3.71 x | 4.08 x | 3.4 x | 4.39 x | 3.93 x | 3.53 x |
| EV / EBITDA | 19 x | 19.3 x | 16.9 x | 21.1 x | 24.5 x | 24.9 x | 21.3 x | 18.4 x |
| EV / FCF | 85.3 x | 120 x | 30.4 x | 55.4 x | 27.1 x | 43.1 x | 35.8 x | 30 x |
| FCF Yield | 1.17% | 0.84% | 3.29% | 1.81% | 3.69% | 2.32% | 2.8% | 3.33% |
| Price to Book | 3.85 x | 4.51 x | 4.49 x | 5.01 x | 4.49 x | 5.75 x | 4.98 x | 4.35 x |
| Nbr of stocks (in thousands) | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | - | - |
| Reference price 2 | 1,751 | 2,326 | 2,770 | 3,621 | 3,396 | 4,910 | 4,910 | 4,910 |
| Announcement Date | 5/30/19 | 6/5/20 | 5/25/21 | 5/13/22 | 5/19/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 73,572 | 83,444 | 88,650 | 106,342 | 115,993 | 129,136 | 142,146 | 156,391 |
| EBITDA 1 | 11,148 | 14,734 | 19,424 | 20,529 | 16,094 | 22,807 | 26,232 | 30,079 |
| EBIT 1 | 9,216 | 12,206 | 16,678 | 17,490 | 12,990 | 19,844 | 22,974 | 26,582 |
| Operating Margin | 12.53% | 14.63% | 18.81% | 16.45% | 11.2% | 15.37% | 16.16% | 17% |
| Earnings before Tax (EBT) 1 | 9,547 | 12,598 | 18,421 | 18,443 | 13,048 | 21,419 | 25,213 | 29,467 |
| Net income 1 | 7,605 | 11,271 | 15,850 | 16,456 | 9,842 | 18,672 | 21,700 | 25,081 |
| Net margin | 10.34% | 13.51% | 17.88% | 15.47% | 8.48% | 14.46% | 15.27% | 16.04% |
| EPS 2 | 63.61 | 94.26 | 132.6 | 137.6 | 82.31 | 153.1 | 180.3 | 207.5 |
| Free Cash Flow 1 | 2,482 | 2,374 | 10,804 | 7,830 | 14,528 | 13,158 | 15,632 | 18,411 |
| FCF margin | 3.37% | 2.85% | 12.19% | 7.36% | 12.52% | 10.19% | 11% | 11.77% |
| FCF Conversion (EBITDA) | 22.27% | 16.12% | 55.62% | 38.14% | 90.27% | 57.69% | 59.59% | 61.21% |
| FCF Conversion (Net income) | 32.64% | 21.07% | 68.17% | 47.58% | 147.62% | 70.47% | 72.04% | 73.41% |
| Dividend per Share 2 | 16.00 | 25.00 | 28.00 | 34.00 | 25.00 | 43.38 | 48.74 | 54.29 |
| Announcement Date | 5/30/19 | 6/5/20 | 5/25/21 | 5/13/22 | 5/19/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23,180 | 21,922 | 27,314 | 28,000 | 26,190 | 24,839 | 25,764 | 30,794 | 30,409 | 29,026 | 29,677 | 33,575 | 32,679 | 31,959 |
| EBITDA 1 | 5,291 | 2,911 | 5,929 | 6,244 | 4,985 | 3,372 | 2,032 | 4,539 | 5,990 | 3,532 | 3,892 | 5,371 | 6,025 | 4,634 |
| EBIT 1 | 4,601 | 2,226 | 5,223 | 5,516 | 4,210 | 2,541 | 1,270 | 3,765 | 5,206 | 2,749 | 3,168 | 4,722 | 5,200 | 4,496 |
| Operating Margin | 19.85% | 10.15% | 19.12% | 19.7% | 16.07% | 10.23% | 4.93% | 12.23% | 17.12% | 9.47% | 10.67% | 14.06% | 15.91% | 14.07% |
| Earnings before Tax (EBT) 1 | 5,434 | 2,582 | 5,561 | 5,815 | 4,639 | 2,427 | 1,519 | 4,023 | 5,389 | 2,117 | 3,528 | 4,800 | 5,500 | 4,596 |
| Net income 1 | 4,510 | 2,400 | 4,681 | 5,443 | 5,257 | 1,076 | 1,276 | 3,308 | 4,547 | 709.8 | 2,867 | 4,005 | 4,711 | 3,682 |
| Net margin | 19.45% | 10.95% | 17.14% | 19.44% | 20.07% | 4.33% | 4.95% | 10.74% | 14.95% | 2.45% | 9.66% | 11.93% | 14.42% | 11.52% |
| EPS | 37.72 | 20.07 | 39.15 | 45.52 | 43.96 | 9.000 | 10.68 | 27.67 | 38.03 | - | - | 28.50 | - | 34.00 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/5/21 | 5/25/21 | 8/6/21 | 11/12/21 | 2/4/22 | 5/13/22 | 8/5/22 | 11/11/22 | 2/10/23 | 5/19/23 | 8/10/23 | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 2,410 | 5,705 | - | 896 | - | - | - | - |
| Net Cash position 1 | - | - | 2,569 | - | 12,202 | 20,120 | 27,855 | 34,375 |
| Leverage (Debt/EBITDA) | 0.2162 x | 0.3872 x | - | 0.0437 x | - | - | - | - |
| Free Cash Flow 1 | 2,483 | 2,374 | 10,805 | 7,830 | 14,528 | 13,158 | 15,632 | 18,411 |
| ROE (net income / shareholders' equity) | 14.8% | 19.4% | 23.4% | 20.7% | 15.9% | 18.5% | 18.8% | 18.7% |
| ROA (Net income/ Total Assets) | 9.58% | 12.4% | 14.8% | 13% | 10.1% | 13.1% | 13.5% | 14% |
| Assets 1 | 79,369 | 90,761 | 107,324 | 126,892 | 97,269 | 143,081 | 160,620 | 179,374 |
| Book Value Per Share 2 | 455.0 | 515.0 | 617.0 | 723.0 | 757.0 | 854.0 | 985.0 | 1,130 |
| Cash Flow per Share 2 | 65.00 | 48.90 | 106.0 | 92.90 | 141.0 | 84.70 | 119.0 | 150.0 |
| Capex 1 | 5,269 | 3,476 | 1,845 | 3,280 | 2,297 | 3,352 | 3,725 | 3,910 |
| Capex / Sales | 7.16% | 4.17% | 2.08% | 3.08% | 1.98% | 2.6% | 2.62% | 2.5% |
| Announcement Date | 5/30/19 | 6/5/20 | 5/25/21 | 5/13/22 | 5/19/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
4,910
INR
Average target price
5,184
INR
Spread / Average Target
+5.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.13% | 7.04B | |
| +25.56% | 661B | |
| +26.74% | 566B | |
| -6.57% | 352B | |
| +20.29% | 332B | |
| +3.01% | 283B | |
| +13.43% | 231B | |
| +4.70% | 200B | |
| -9.41% | 195B | |
| -5.26% | 145B |
- Stock Market
- Equities
- ALKEM Stock
- Financials Alkem Laboratories Limited
